Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey (PANORAMA)

AstraZeneca

Status: Completed

Conditions: Diabetes

Study type: Observational

Funder types: Industry

Identifiers

NCT00916513

NIS-CEU-DUM-2008/2

Details and patient eligibility

About

The present European survey seeks to assess quality of life and satisfaction with treatment in people with T2DM and to appreciate disease and treatment variables including hypoglycaemia and level of glycaemic control. It will also provide relevant information on other important aspects such as the level of correlation of objective measures such as HbA1c with health status, QoL and satisfaction with current treatment. Overall 5000 randomly selected patients will be invited to participate from a representative sample of clinical practices during a pre-specified period. The study will entail a single patient visit. Patients who agree to the study and give their informed consent will complete questionnaires which, combined with retrospective notes review & an HbA1c test, will allow patient, disease and treatment variables to be collected. An HbA1c test is a finger prick test to measure glycosylated haemoglobin in the blood indicating the level of blood glucose over the last 8-12 weeks.

Enrollment: 5,926 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• With T2DM, diagnosed at least 1 year prior to entry in the study
• Currently treated with diet, OAD(s) and/or insulin with no change in the type of OAD(s) or insulin in the previous three months

Exclusion criteria

• Type 1 diabetes and/or history of diabetic ketoacidosis
• Secondary diabetes (including disease of the exocrine pancreas, endocrinopathies or drug-induced)
• Treatment with systemic glucocorticoids other than replacement therapy. Inhaled, local injected and topical use of glucocorticoids is allowed

Trial design

5,926 participants in 1 patient group

1

Description:

Patients ³ 40 years old, with T2DM diagnosed and followed up in the participating site at least 1 year prior to entry in the study, treated with diet, OADs and/or insulin for at least the past three months